

CLINICAL COMPENDIUM

Advancing the Care of Patients With Type 2 Diabetes and Chronic Kidney Disease: Role of the Glucagon-Like Peptide-1 Receptor Agonists



Clinical Resources

[American Diabetes Association. Kidney Disease \(Nephropathy\).](#)

[American Society of Nephrology. Diabetic Kidney Disease Collaborative.](#)

[Centers for Disease Control and Prevention. Diabetes and Chronic Kidney Disease.](#)

[Davies MJ, et al. Management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association \(ADA\) and the European Association for the Study of Diabetes \(EASD\). *Diabetes Care*. 2022;45\(11\):2753-2786](#)

[de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association \(ADA\) and Kidney Disease: Improving Global Outcomes \(KDIGO\) 2022. *Diabetes Care*. 2022;45\(12\):3075-3090.](#)

[Górriz JL, Soler MJ, Navarro-González JF, et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. *J Clin Med*. 2020;9\(4\):947.](#)

[National Institute of Diabetes and Digestive and Kidney Diseases. Diabetic Kidney Disease.](#)

[National Kidney Foundation. Preventing Diabetic Kidney Disease: 10 Answers to Questions.](#)

[Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. *Ther Adv Endocrinol Metab*. 2021;12:2042018821997320.](#)

[Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9\(10\):653–662.](#)